Please ensure Javascript is enabled for purposes of website accessibility

Philip Morris, Altria Are Facing ITC Investigations; What Should Investors Know?

By Michael Dean McGrady Jr – Updated May 18, 2020 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The U.S. International Trade Commission has announced a probe into Altria and Philip Morris for alleged patent violations over iQOS heat-not-burn technology.

Altria Group (MO -1.64%) is having a tough few weeks. After reporting tepid first-quarter earnings results April 30, the tobacco giant is now facing an investigation from the U.S. International Trade Commission (ITC). 

Along with Philip Morris International (PM -2.12%), Altria is facing an inquiry after three business units of British American Tobacco (BTI -0.52%) filed a complaint with the ITC regarding an alleged infringement of patents pertaining to the technology of heated tobacco products. 

For you newbies, a heated tobacco product, at times known as a heat-not-burn (HnB) device, is a smoke-free answer to traditional tobacco cigarettes. 



These devices heat the substance inside until it evaporates, distributing an aerosol that is considered less harmful than smoke. HnB devices are similar to e-cigarettes and vaping products, which vaporize a water-based liquid laced with preservatives and nicotine. However, HnB products are used with specially designed tobacco sticks that respond to the heating and evaporation process that's built in. 

Problems over patents

Hands down, one of the world's most popular heat-not-burn products is PMI's iQOS system, which was only recently approved for sale in a few select local markets in the United States through an arrangement with Altria under the latter's Marlboro brand. 

Given the shrinking market for traditional cigarettes in the U.S., iQOS could be a massive boon for PMI and Altria. But British American Tobacco alleges that the product infringes on its patents and intellectual property.

In response to the filing, the ITC said it found grounds to scrutinize PMI and Altria's import and patent activities. Its investigation, to determine whether PMI and Altria violated section 337 of the Tariff Act of 1930, will be carried out by the commission's Office of Unfair Import Investigations.  Section 337 prohibits imports from companies that could likely infringe upon the authority of a U.S. patent owned by another person or entity.

In addition to the complaint filed with the ITC and another put forth in Germany, British American Tobacco filed a lawsuit in a federal district court in Virginia to take on the alleged infringement. BAT and its tobacco and e-vapor units want iQOS products banned in the U.S. unless PMI and Altria agree to pay out on a license to use the patents in question to maintain iQOS sales. 

Poor news for investors?

The U.S. Food and Drug Administration (FDA) approved PMI and Altria's premarket tobacco applications for iQOS in 2019, affirming that the companies could begin selling iQOS devices and heat sticks (the tobacco) in select cities late in the year. If the ITC ends up enacting a ban on imports of the product for patent infringement reasons, it could be an embarrassment for two of the world's largest tobacco companies.

From an investing standpoint, the investigation may be worrisome for investors of Altria and PMI. Again, Altria's first-quarter earnings were tepid; sales of the iconic Marlboro brand were down more than 1% this quarter compared with last year. PMI's first-quarter earnings, meanwhile, showed a slight decline in shares for the retail cigarette segment, while iQOS was a bright spot.

Criminal investigations

British American Tobacco is itself the subject of a criminal investigation led by the U.S. Department of Justice and the Treasury Department, alleging that the company breached international sanctions by doing business with nations including Cuba and Iran.

That said, of all the companies involved in this dispute, British American Tobacco and its units look the most like a buy. That's especially true given BAT's coronavirus vaccine candidate, which is poised to enter human trials. Investors interested in the tobacco space will want to look closely at the moves each company is making beyond traditional cigarettes.

Michael McGrady has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altria Group, Inc. Stock Quote
Altria Group, Inc.
$40.79 (-1.64%) $0.68
Philip Morris International Inc. Stock Quote
Philip Morris International Inc.
$87.02 (-2.12%) $-1.88
British American Tobacco p.l.c. Stock Quote
British American Tobacco p.l.c.
$36.08 (-0.52%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.